Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating mitoxantrone hydrochloride liposome plus rituximab and lenalidomide (M+R2) in relapsed/refractory diffuse large B-cell lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Mitoxantrone hydrochloride liposome (Mitoxantrone hydrochloride liposome)
• Rituximab (rituximab)

Snippet

Sponsor: Jianfeng Zhou | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN